Showing results (81-90 of 176) with videos related to
Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|September 23, 2015
Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancersWen-zhao Zhong, Jian Su, Fang-ping Xu, et al.Discover Oncology|May 27, 2026
Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skippingJiao Yang, Cheng-Di Weng, Han-Min Wang, et al.The Lancet. Respiratory Medicine|April 15, 2019
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 studyCaicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, et al.Clinical Lung Cancer|December 15, 2020
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)Xiang-Meng Li, Wen-Feng Li, Jun-Tao Lin, et al.Genes, Chromosomes & Cancer|October 23, 2021
Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter studyJin Kang, Qiu-Mei Deng, Kai-Cheng Peng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung AdenocarcinomaChao Zhang, Jianjun Zhang, Fang-Ping Xu, et al.World Journal of Surgical Oncology|January 11, 2017
Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective studySong Dong, Ning Zhao, Wei Deng, et al.The Lancet. Respiratory Medicine|July 24, 2017
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trialJin-Ji Yang, Caicun Zhou, Yisheng Huang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2018
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung CancerYi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.Pageof 18